Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jan 24, 2007

Kirin and Astellas Partner to Develop Immunosuppressive Mab

  • Kirin Brewery Company and Astellas Pharma will exclusively partner in developing and marketing a fully human anti-CD40 antagonistic Mab worldwide.

    Kirin discovered this CD40 antagonistic Mab and reports that it has shown strong immunosuppressive activity in preclinical studies.

    Under the terms of the license and collaborative R&D agreement, Kirin will receive an upfront payment as well as milestone payments. The companies will share the R&D costs. Astellas has the right to sell the product, and Kirin has the right to co-promote it, both on a worldwide basis.  The companies will share the profits on worldwide sales. Kirin, however, retains co-marketing rights in Japan, and each party will pay the other a royalty instead of profit sharing.



Be sure to take the GEN Poll

Cancer vs. Zika: What Worries You Most?

While Zika continues to garner a lot of news coverage, a Mayo Clinic survey reveals that Americans believe the country’s most significant healthcare challenge is cancer. Compared to other diseases, does the possibility of developing cancer worry you the most?

More »